The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i>

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i>

Aim of the Study. To analyze the predictive value of the genetic polymorphisms in rs8099917 and rs12979860 loci of the IL28В gene for the assessment of the efficacy prognosis of the combined antiviral therapy on the basis of the standard Interferon of the patients with Chronic Hepatitis C (CHC).Mate...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Lapshin, M. V. Mayevskaya, V. T. Ivashkin, P. O. Bogomolov, I. G. Nikitin, O. O. Znoyko
Format:	Article
Language:	Russian
Published:	Gastro LLC 2013-03-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	chronic hepatitis c genetic polymor- phisms il28b gene antiviral treatment interferon-α ribavirin virology response
Online Access:	https://www.gastro-j.ru/jour/article/view/1180
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy
by: V. E. Syutkin, et al.
Published: (2011-12-01)

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection
by: N. D. Yuschuk, et al.
Published: (2009-02-01)

Results of the ORION open comparative randomized trial: evaluation of efficacy of the Russian drugs Altevir and Phosphogliv in combined treatment of chronic hepatitis C
by: V. T. Ivashkin, et al.
Published: (2012-11-01)

Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01)

Role of Interleukin-28B in clearance of HCV in acute and chronic hepatitis patients in Kirkuk city
by: Muhannad Abdullah Alazzawy
Published: (2018-07-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy
by: P. O. Bogomolov, et al.
Published: (2024-12-01)

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study
by: D. T. Abrurakhmanov, et al.
Published: (2014-07-01)

Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01)

Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C
by: S. N. Batskikh
Published: (2012-11-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Modern modes of chronic hepatitis C treatment
by: V. T. Ivashkin, et al.
Published: (2012-02-01)

Sarcoid-like reaction at the patient with chronic hepatitis C on a background of antiviral therapy
by: A. V. Lapshin, et al.
Published: (2010-06-01)

Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C
by: V. T. Ivashkin, et al.
Published: (2023-06-01)

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy
by: K. R. Dudina, et al.
Published: (2023-02-01)

Optimized production and antiviral activity evaluation of recombinant chicken interferon-alpha using an improved Baculovirus expression system
by: Yuxia Zhang, et al.
Published: (2025-03-01)

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01)

Antivirals for the treatment of mild and moderate COVID-19 in South Africa
by: R Perumal, et al.
Published: (2023-12-01)

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome
by: Kira A Cozzolino, et al.
Published: (2025-02-01)

Antiviral therapy and regression of liver fibrosis at chronic hepatitis B
by: D. T. Abdurakhmanov
Published: (2010-02-01)

Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-12-01)

Potentials of antiviral therapy at patients with liver cirrhosis in an outcome of HCV-infection
by: E. N. Bessonova
Published: (2011-06-01)

“I definitely cannot afford to be feeling poorly if there’s no need to be”: a qualitative evaluation of antiviral uptake following suspected occupational exposure to avian influenza
by: Riinu Pae, et al.
Published: (2025-02-01)

Il significato della metafora di cuore nella spiritualità di Teofane il Recluso (1815–1894)
by: Pavlo Fitsay
Published: (2017-10-01)

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01)

Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern EuropeansResearch in context
by: Ben Krause-Kyora, et al.
Published: (2025-03-01)

Proinflammatory Tear Cytokines in Human Adenoviral Keratoconjunctivitis and Clinical Eye Severity
by: Santacruz Valdés C, et al.
Published: (2025-02-01)

Association between serum total bilirubin levels and 28-day all-cause mortality after intracerebral hemorrhage
by: Dachang Qiu, et al.
Published: (2025-02-01)

Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience)
by: I. Yu. Pirogova, et al.
Published: (2018-08-01)

Diagnostic value of cerebrospinal fluid levels of D-lactate, tumour necrosis factor-alpha and interleukin-6, -8, and -17 in suspected nosocomial meningitis
by: Sibel Yorulmaz Goktas, et al.
Published: (2024-08-01)

Developing an Optimal Antiviral Method for the Air-filtration System of Subway Stations
by: Dae Hoon Park, et al.
Published: (2023-05-01)

Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis
by: Loïs Bolko, et al.
Published: (2025-02-01)

Genetic polymorphism of xenobiotic biotransformation genes, TNF-α and IL-4 in obstructive jaundice
by: A. A. Natalsky, et al.
Published: (2015-09-01)

Recent trends in studying of alcohol-induced liver disease
by: I. I. Komkova, et al.
Published: (2011-12-01)

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study
by: Guanghui Ren, et al.
Published: (2025-02-01)

Preliminary results of open comparative randomized study PHG-M3/P01-09 «ORION» on application of «Phosphogliv» in combined therapy of chronic hepatitis C
by: M. V. Mayevskaya
Published: (2011-06-01)

IL-6/GATA2/SERPINE1 pathway is implicated in regulating cellular senescence after acute kidney injury
by: Hongshuang Su, et al.
Published: (2025-02-01)

Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches
by: Ayyaz Khan, et al.
Published: (2025-02-01)

Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-03-01)

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms
by: Nicholas L. Calistri, et al.
Published: (2025-02-01)